Revive Therapeutics (RVV) AI Stock Analysis

• Market Cap: C$6.28M
• Dividend Yield: N/A
• Average Volume (3M): 285.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.61
• Revenue Growth: N/A
• EPS Growth: -80.42%
• Country: CA
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 418,564,270
• 10 Day Avg. Volume: 295,136
• 30 Day Avg. Volume: 285,498
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.02 ▲(50.00% Upside)

The score is primarily constrained by very weak financial performance (no revenue, ongoing losses/cash burn, and negative equity with sharply reduced assets), which increases financing risk. Technicals are modestly supportive in the short term but remain weaker over longer moving averages, and valuation metrics are not supportive due to losses and no dividend yield provided.

Positive Factors

Financial Management

The Shares for Debt transaction reflects prudent financial management, conserving cash for operations and supporting strategic initiatives, which is crucial for sustaining long-term development efforts in the absence of current revenue.

Strategic Collaborations

The collaboration to explore Bucillamine's role in cancer treatment could lead to significant advancements in oncology, potentially opening new markets and enhancing Revive's competitive edge in the biopharmaceutical sector.

Pipeline Expansion

The acquisition of the molecular hydrogen program expands Revive's pipeline, potentially enhancing its position in neurological and mental health treatments, which could lead to future revenue streams and strengthen its market position.

Negative Factors

Ongoing Losses

Continuous operating losses and negative gross profit margins indicate significant financial challenges, threatening Revive's ability to achieve profitability and necessitating strategic shifts to improve financial performance.

Negative Cash Flow

Sustained negative cash flow from operations is unsustainable and highlights the urgent need for Revive to achieve positive cash generation to support its business model and reduce reliance on external financing.

No Revenue Generation

The absence of revenue generation poses a significant risk to long-term sustainability, as it limits the company's ability to fund operations and invest in growth without relying on external financing.

Revive Therapeutics Business Overview & Revenue Model

Company Description

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

How the Company Makes Money

Revive Therapeutics generates revenue through the development and commercialization of novel therapeutics. The company's revenue model is based on the successful progression of its drug candidates through clinical trials, leading to licensing agreements, partnerships, or sales upon regulatory approval. Key revenue streams include milestone payments from strategic collaborations, licensing fees, and potential royalties from commercialized products. Additionally, Revive collaborates with other pharmaceutical companies and research institutions to enhance its development pipeline, attracting funding and sharing development costs, which further contributes to its earnings.

Revive Therapeutics Financial Statement Overview

Summary

Revive Therapeutics faces significant financial challenges with no revenue and continuous operating losses. The company has relied on equity financing to sustain its operations, but declining cash reserves and equity suggest a critical need for strategic shifts to generate revenue and improve cash flow. The lack of revenue growth and profitability could pose long-term sustainability risks if not addressed.

Income Statement

Revive Therapeutics has shown no revenue generation over the last several years, resulting in consistently negative gross profit. The negative EBIT and EBITDA margins indicate significant operating losses. The company reported substantial net losses across the periods reviewed, indicating ongoing financial challenges and the need for revenue growth to improve profitability.

Balance Sheet

The balance sheet reflects a relatively stable equity base with no current debt obligations, which is a positive indicator of financial health. However, the shrinking of total assets over time and the consistent reduction in stockholders' equity suggest a potential depletion of resources. The company has maintained an equity ratio suggesting reliance on equity financing, but the reduction in cash reserves is concerning.

Cash Flow

The cash flow statements reveal negative operating cash flows, indicating cash outflows from operations, which is unsustainable long-term without revenue generation. The company has managed to secure financing to cover its operational deficits, but the lack of free cash flow growth is a significant concern. The absence of positive operating cash flow underscores the need for strategic changes to improve cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-170.00	-248.00	-328.00	-434.00	-578.00	-775.00
EBITDA	-10.82M	-11.01M	-5.60M	-5.52M	-17.74M	-18.57M
Net Income	-10.82M	-11.01M	-5.62M	-6.32M	-17.83M	-20.20M
Balance Sheet
Total Assets	249.81K	205.02K	10.64M	14.25M	17.07M	29.81M
Cash, Cash Equivalents and Short-Term Investments	30.95K	24.56K	773.07K	2.09M	3.92M	16.60M
Total Debt	68.18K	66.87K	25.22K	219.69K	327.73K	415.84K
Total Liabilities	3.75M	3.66M	3.40M	3.60M	4.46M	999.68K
Stockholders Equity	-3.50M	-3.46M	7.23M	10.65M	12.60M	28.81M
Cash Flow
Free Cash Flow	-440.00K	-807.66K	-3.29M	-6.03M	-13.06M	-11.31M
Operating Cash Flow	-440.00K	-807.66K	-3.29M	-6.03M	-13.06M	-8.31M
Investing Cash Flow	0.00	-30.00K	0.00	0.00	0.00	-2.72M
Financing Cash Flow	187.95K	39.15K	1.98M	4.20M	376.35K	26.24M

Revive Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVV, the sentiment is Positive. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.00 is Neutral, neither overbought nor oversold. The STOCH value of 200.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RVV.

Revive Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVMD	46 Neutral	C$5.29M	-0.71	-148.48%	―	-46.59%	8.26%
RAMM	45 Neutral	C$4.78M	-0.36	-69.77%	―	-15.51%	-49.26%
RVV	44 Neutral	C$6.28M	-0.58	-664.21%	―	―	-80.42%
PCLO	44 Neutral	C$15.39M	-2.79	―	―	15.64%	58.47%
FFNT	39 Underperform	C$4.58M	-0.18	―	―	―	―
AYUR	38 Underperform	C$3.89M	-0.89	-271.33%	―	15.95%	-1.81%

Revive Therapeutics Corporate Events

Revive Therapeutics Updates on Nerve Agent Countermeasure Study

Revive Therapeutics has announced an update on its research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in collaboration with Defence R&D Canada. The study is expected to conclude in January 2026, with findings to be released upon authorization from DRDC. This collaboration highlights Revive’s strategic focus on developing medical countermeasures and could enhance its positioning in the life sciences industry.

Revive Therapeutics Updates on Nerve Agent Countermeasure Study

Revive Therapeutics announced an update on its ongoing study of Bucillamine as a potential treatment for nerve agent exposure, conducted in collaboration with Defence R&D Canada. The study is still in progress, and the final findings will be released with DRDC’s authorization. This research could strengthen Revive’s position in developing medical countermeasures, potentially impacting stakeholders interested in innovative treatments for nerve agent-induced injuries.